Wednesday, July 16, 2025 7/16/2025

Obesity-induced dysfunction of human MSC in peripheral microvascular repair

Award Number: R01HL158691
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2022
PERIOD OF PERFORMANCE END DATE: 06/30/2027

Group Awards By:

View Award Description

Obesity-induced dysfunction of human MSC in peripheral microvascular repair - Abstract Obesity triggers cellular damage and impedes tissue recovery from injury, and its escalating prevalence may promote complications of peripheral vascular disease, such as critical limb ischemia (CLI) or renal artery stenosis (RAS). Reducing complications of obesity could diminish the risk of death, improve quality of life, and produce extensive cost savings. This application is based on the scientific premise that obesity increases tissue susceptibility to injury by interfering with normal defense and repair processes associated with mesenchymal stem/stromal cells (MSCs). MSCs constitute an effective endogenous cellular repair system, but obesity may blunt their efficacy. We found that obesity-induced MSC dysfunction in pigs was associated with altered mitochondrial structure and function, but the mechanisms of mitochondrial damage in human MSC and its contribution to regulation of MSC function in human obesity remain unknown. Our central hypothesis is that human obesity engages epigenetic mechanisms that impair human MSC mitochondrial structure and function and render MSC functionally deficient. We speculate that obesity alters in MSC the epigenetic states of micro-RNA (miR) miR-181a, a key miR that targets mitochondrial DNA and negatively regulates their function. A consequent fall in levels of the mitochondrial derived peptide (MDP) MOTS-c in turn impairs function and tissue repair capacity of MSC in obesity. To test our hypothesis, we will define gene expression and epigenetic states of mitochondrial targeting miRNAs and MOTS-c in human adipose tissue-derived MSC and elucidate their functional significance for both MSCs and their mitochondria. Our Specific Aims will pursue 3 hypotheses. Aim 1: Human obesity induces MSC miR-181a expression and in turn mitochondrial and MSC structural damage and dysfunction. Using RNA-seq we will identify miR-181a as a key miR upregulated in MSCs from patients with obesity vs. healthy controls. Its role in regulating MSC and mitochondrial function and structure will be assessed in vitro and in vivo (in mice with CLI or RAS) using novel in vivo imaging and ex vivo techniques. Aim 2: Human obesity engages epigenetic mechanisms to alter miR- 181a. We will define the epigenetic landscape of miR-181a using MeDIP-seq, and its contribution to MSC repair in vitro and in vivo using an epigenetic modifier. Aim 3: A fall in MOTS-c owing to mitochondrial damage contributes to functional impairment of ‘obese MSC’. Using novel MDP-seq we will pinpoint MOTS-c as a unique MDP linking mitochondrial to cellular integrity in MSC. MSC treated with MOTS-c peptide or neutralizing antibody will be characterized, and restoration of ‘obese’ MSC function tested both in vitro and in vivo. The proposed studies, employing cutting edge techniques, may uncover novel mechanisms underlying cell damage and impaired repair in human obesity. These studies will advance understanding of the pathogenesis of cellular damage, and likely contribute towards management of patients with obesity and vascular disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $678,004 )
2024	2024	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cardiovascular Diseases Research	000	3	6/27/2024	NON-COMPETING CONTINUATION	$678,004
														Subtotal = $678,004

Issue Date FY: 2023 ( Subtotal = $691,842 )
2023	2023	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cardiovascular Diseases Research	000	2	6/20/2023	NON-COMPETING CONTINUATION	$691,842
														Subtotal = $691,842

Issue Date FY: 2022 ( Subtotal = $706,592 )
2022	2022	MAYO CLINIC	200 FIRST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cardiovascular Diseases Research	000	1	6/24/2022	NEW	$706,592
														Subtotal = $706,592

Grand Total All Awards = $2,076,438

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Obesity-induced dysfunction of human MSC in peripheral microvascular repair

Award Number: R01HL158691

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2022

PERIOD OF PERFORMANCE END DATE: 06/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer